GPN Vaccines

Adelaide, Australia

GPN Vaccines is a vaccine that is used to prevent the spread of streptococcus pneumoniae.

$12.0M raised

Jun 2024

Series B

Top Investors

Forepont Capital PartnersShearwater CapitalNational Health and Medical Research CouncilKern Whelan CapitalGovernment of South Australia

Founder Contacts

19,000+ verified contacts

Get Instant Access

Emails, phones & LinkedIn profiles

Frequently Asked Questions about GPN Vaccines

How much funding has GPN Vaccines raised?

GPN Vaccines has raised $12.0M in total funding. The most recent round was Series B. The last funding was announced in June 2024.

Who are GPN Vaccines's investors?

GPN Vaccines's investors include Forepont Capital Partners, Shearwater Capital, National Health and Medical Research Council, Kern Whelan Capital, Government of South Australia.

Where is GPN Vaccines headquartered?

GPN Vaccines is headquartered in Adelaide, Australia.

What does GPN Vaccines do?

GPN Vaccines is a vaccine that is used to prevent the spread of streptococcus pneumoniae.

What stage is GPN Vaccines at?

GPN Vaccines is at the Series B stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated June 6, 2024.

MLA

"GPN Vaccines — Funding & Investors." VCBacked, June 6, 2024, https://www.vcbacked.co/company/gpn-vaccines. Accessed June 24, 2026.

APA

VCBacked. (2024). GPN Vaccines — Funding & Investors. Retrieved June 24, 2026, from https://www.vcbacked.co/company/gpn-vaccines

Wikipedia (cite web)

{{cite web |title=GPN Vaccines — Funding & Investors |url=https://www.vcbacked.co/company/gpn-vaccines |website=VCBacked |access-date=June 24, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated June 6, 2024.

Similar Companies in Biotechnology